On November 8, 2019 Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported that the Company has issued its October 2019 Corporate Update Letter (Press release, Citius Pharmaceuticals, NOV 8, 2019, View Source [SID1234550770]). The Letter highlights the progress of the Company’s product candidates Mino-Lok, Mino-Wrap, and Halo-Lido, along with details on its strategic goals to develop breakthrough technologies to improve and enhance the lives of patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Company Highlights include:

Closing on a recent $7 million capital raise to advance ongoing research
A recent modification to the primary endpoint of the pivotal Phase III trial for Mino-Lok that substantially reduced the required trial sample size from 700 to approximately 144 subjects, significantly reducing the trial’s expense and accelerating its completion
An expanded relationship with MD Anderson Cancer Center for a worldwide license for Mino-Wrap and the preparation for a pre-IND meeting with the FDA
Reformulating the topical formulation (now Halo-Lido) for the treatment of hemorrhoids based on results from an initial Phase II study. A toxicology study will be initiated by year-end ahead of an expanded Phase II study to start in 2020
Other corporate initiatives that include industry events and investor outreach
To view the Company’s Corporate Update Letter in its entirety, please visit: View Source